Takeda is taking advantage of the huge growth in the so-called pharmerging nations and has unveiled plans to enter the Indian market as it faces patent expiry of its biggest selling drug Actos (pioglitazone) early next year.

In November, the company revealed it hopes to snap up a South American generics drugmaker and the previous month announced it plans to open up offices in Brazil, India and Russia.

Takeda will set up a team to research the Indian market, the country’s Financial Express noted, with the firm on the look out for partnering or acquisition opportunities.

Yasuchika Hasegawa, who was making a speech about the country’s corporate management practices at the Foreign Correspondents' Club of Japan in Tokyo earlier this year, also pointed out that Takeda is not interested in getting into the Japanese generic drug market. This targeting of the emerging markets mirrors an approach being looked at by fellow Japanese firm Eisai, whose chief executive, Haruo Naito, told PharmaTimes World News earlier this year that the firm is interested in branded generics to cater specifically for the middle-income class of China and India.

According to IMS, the seven 'pharmerging' countries of Brazil, China, India, Mexico, Russia, South Korea and Turkey are expected grow 12%-14% in 2010, and 13%-16% over the next five years. China will lead the pack with 20%-plus growth.